PDL reports progress on two humanised antibodies
Protein Design Labs (PDL) has reported encouraging findings from clinical studies of two humanised antibodies being evaluated in ulcerative colitis and Crohn's disease, the two principal forms of inflammatory bowel disease.
Protein Design Labs (PDL) has reported encouraging findings from clinical studies of two humanised antibodies being evaluated in ulcerative colitis and Crohn's disease, the two principal forms of inflammatory bowel disease.
PDL reported that a strong signal of activity was observed in both doses tested in a Phase I clinical trial of visilizumab (Nuvion) in patients with severe ulcerative colitis. The company also reported that fontolizumab (HuZAF) did not meet the primary endpoint at study day 28 in two Phase II clinical trials (Harmony I and Harmony II) in Crohn's disease following administration of a single intravenous dose. HuZAF, however, demonstrated statistically greater activity compared with placebo at several subsequent time points following administration of a second intravenous dose.
Dr Steve Benner said: 'We believe that results from these studies support our efforts to build a franchise in inflammatory bowel disease and to provide innovative new therapies for patients. We look forward to the continued development of these novel agents in areas of significant unmet medical need.'